← Back to Search

Medication Adherence Intervention for Myocardial Ischemia and Rheumatic Diseases (SEPPRMACI-ARM Trial)

N/A
Waitlist Available
Led By Liron Caplan, MD PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a medication adherence intervention for Veterans with ischemic heart disease and rheumatic disease. The intervention will use personalized text messages and telephone calls to remind patients to refill their medications.

Who is the study for?
This trial is for Veterans with ischemic heart disease who've had a PCI or are starting anti-rheumatic medication. They must be taking specific meds, get care from the VA, and have a VA-assigned primary care provider. It's not for those only diagnosed via catheterization, prisoners, pregnant women, terminally ill patients, those using non-VA medicine sources or in nursing facilities, or individuals with impaired decision-making.
What is being tested?
The study tests an adherence intervention called VA SEPPRMACI-ARM to improve how well Veterans with IHD follow their medication plans after PCI or when starting anti-rheumatic drugs. It uses personalized texts and calls to remind patients about refills and escalates to personal contact if they miss doses.
What are the potential side effects?
Since this trial focuses on improving medication adherence rather than testing new medications themselves, side effects would relate primarily to the underlying treatments for IHD or rheumatic diseases rather than the intervention being tested.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Days Covered (PDC)
Secondary study objectives
Cardiovascular Events (CVE)
Incremental Cost Effectiveness (ICE)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental GroupExperimental Treatment1 Intervention
This group will undergo the intervention as described in the protocol
Group II: Control GroupActive Control1 Intervention
This group will not receive the intervention, they will receive usual care

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,658 Previous Clinical Trials
3,356,344 Total Patients Enrolled
6 Trials studying Myocardial Ischemia
4,566 Patients Enrolled for Myocardial Ischemia
Liron Caplan, MD PhDPrincipal InvestigatorRocky Mountain Regional VA Medical Center, Aurora, CO
~580 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top